Pseudohypoparathyroidism Market

Market Overview:

The 7 major pseudohypoparathyroidism markets reached a value of USD 104.1 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 180.7 Million by 2035, exhibiting a growth rate (CAGR) of 5.17% during 2025-2035.

The pseudohypoparathyroidism market has been comprehensively analyzed in IMARC's new report titled "Pseudohypoparathyroidism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Pseudohypoparathyroidism is an uncommon genetic endocrine disorder involving the resistance of the body to parathyroid hormone (PTH), which causes hypocalcemia, hyperphosphatemia, and skeletal deformity. It is mostly due to mutations in the GNAS gene, which compromises PTH signaling, causing low levels of calcium despite high or normal levels of PTH. The disorder appears early in life with features like cramps in muscles, tetany, dental abnormalities, shortness of stature, obesity, round face, developmental delay, and insensitivity to other hormones such as thyroid-stimulating hormone (TSH). The patient can also have Albright's hereditary osteodystrophy (AHO) syndrome that is characterized by brachydactyly, soft tissue calcification, and mental retardation. Because of the diversified clinical presentation, diagnosis is generally delayed, for which a battery of biochemical tests, genetic tests, and imaging procedures are used. Laboratory examination characteristically has low serum calcium, elevated phosphate, and PTH levels, whereas skeletal X-rays and DXA help identify bone deformity. Early treatment and diagnosis help prevent complications and enhance long-term results in the patient.

Growing incidence of genetic disorders and rising awareness of uncommon endocrine disorders are the major drivers of the pseudohypoparathyroidism market. The development in molecular diagnostics and genetic testing is facilitating early and accurate diagnosis, decreasing the rate of misdiagnosis, and improving patient outcomes. Moreover, the increasing use of recombinant PTH analogs, calcitriol, and phosphate binders is improving disease management by sustaining calcium and phosphate homeostasis. The availability of new therapeutic options, like long-acting PTH analogues and intracellular signaling pathway-targeting small molecules, is also driving the growth of the market. Supportive therapy, like calcium and vitamin D supplementation, is still crucial in controlling chronic symptoms, preventing skeletal deformities, and enhancing patient quality of life. The growing emphasis on gene therapy research and personalized medicine is likely to introduce novel treatments to the market, which may treat the root genetic mutations. Additionally, enhanced healthcare infrastructure, positive reimbursement policies, and increased patient access to specialized treatment centers in major markets like the United States, Europe, and Japan are making the market favorable for growth. These are likely to propel the pseudohypoparathyroidism market to register continuous growth during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the pseudohypoparathyroidism market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, Japan has the largest patient pool for pseudohypoparathyroidism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pseudohypoparathyroidism market in any manner.

Key Highlights:

• Pseudohypoparathyroidism is rare, with prevalence ranging from 0.3 to 1.1 cases per 100,000 individuals, varying by region.
• Caused by GNAS gene mutations, it disrupts PTH signaling and is inherited dominantly or arises from spontaneous mutations.
• Symptoms include Albright hereditary osteodystrophy (AHO), short stature, round face, brachydactyly, and subcutaneous ossifications.
• Beyond PTH, resistance to TSH and gonadotropins may occur, leading to multiple endocrine dysfunctions.
• Treatment includes calcium and vitamin D supplementation, with regular monitoring and multidisciplinary care.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the pseudohypoparathyroidism market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the pseudohypoparathyroidism market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current pseudohypoparathyroidism marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the pseudohypoparathyroidism market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the pseudohypoparathyroidism market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the pseudohypoparathyroidism market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035​) of pseudohypoparathyroidism across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of pseudohypoparathyroidism by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of pseudohypoparathyroidism by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with pseudohypoparathyroidism across the seven major markets?
• What is the size of the pseudohypoparathyroidism patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of pseudohypoparathyroidism?
• What will be the growth rate of patients across the seven major markets?

Pseudohypoparathyroidism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for pseudohypoparathyroidism drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pseudohypoparathyroidism market?
• What are the key regulatory events related to the pseudohypoparathyroidism market?
• What is the structure of clinical trial landscape by status related to the pseudohypoparathyroidism market?
• What is the structure of clinical trial landscape by phase related to the pseudohypoparathyroidism market?
• What is the structure of clinical trial landscape by route of administration related to the pseudohypoparathyroidism market?